Comparing the Effectiveness of IV Bezlotoxumab Versus Placebo in Decreasing Morbidity and Mortality in Patients With Fulminant C. Diff Requiring Surgery. | MicrobiomeTrials
Comparing the Effectiveness of IV Bezlotoxumab Versus Placebo in Decreasing Morbidity and Mortality in Patients With Fulminant C. Diff Requiring Surgery.
TERMINATEDPHASE4INTERVENTIONAL
Trial Details
Start: 2019-08-19Est. Completion: 2022-05-23
Enrollment target: 5 participants
Locations
The Ohio State University, Columbus, Ohio, United States
Other microbiome trials you might be interested in